Alternative rapamycin treatment regimens mitigate the impact of rapamycin on glucose homeostasis and the immune system

Inhibition of the mechanistic target of rapamycin (mTOR) signaling pathway by the FDA‐approved drug rapamycin has been shown to promote lifespan and delay age‐related diseases in model organisms including mice. Unfortunately, rapamycin has potentially serious side effects in humans, including glucos...

Full description

Saved in:
Bibliographic Details
Published in:Aging Cell
Main Authors: Arriola Apelo, Sebastian I., Neuman, Joshua C., Baar, Emma L., Syed, Faizan A., Cummings, Nicole E., Brar, Harpreet K., Pumper, Cassidy P., Kimple, Michelle E., Lamming, Dudley W.
Format: Artigo
Language:Inglês
Published: John Wiley and Sons Inc. 2015
Subjects:
Original Articles
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4717280/
https://ncbi.nlm.nih.gov/pubmed/26463117
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/acel.12405
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items